Ship, captain and crew

Ardea Biosciences Inc. believes that its HIV drug candidate, RDEA806, will have a better safety profile, fewer drug-drug interactions and greater activity against drug-resistant viral strains than approved and upcoming products in the NNRTI class.

Last week, the company presented Phase I data at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago. Although RDEA806 is the first compound Ardea has presented since starting operations in late 2006, it hopes to have three other programs in the clinic by year end...